Evaluation of Evolocumab (AMG 145), a Fully Human Anti‐PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment

Evolocumab binds PCSK9, increasing low‐density lipoprotein cholesterol (LDL‐C) receptors and lowering LDL‐C. Target‐mediated evolocumab elimination is attributable to PCSK9 binding. As circulating PCSK9 and LDL‐C levels are primarily regulated by the liver, we compared evolocumab pharmacokinetics, p...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Pharmacol
Main Authors: Gibbs, John P., Slatter, J. Greg, Egbuna, Ogo, Geller, Michelle, Hamilton, Lisa, Dias, Clapton S., Xu, Ren Y., Johnson, Jessica, Wasserman, Scott M., Emery, Maurice G.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2016
Assuntos:
Special Populations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5363371/
https://ncbi.nlm.nih.gov/pubmed/27667740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.832
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares